Data

A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE dataset

Health Data Australia Contributor Records
Sjoquist, Katrin ; Australia New Zealand Gynaecological Oncology Group ; SHP-CTC node
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.25910/EDVB-4889&rft.title=A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE dataset&rft.identifier=http://doi.org/10.25910/EDVB-4889&rft.publisher=University of Sydney&rft.description=This dataset includes 24 female participants (38 86 years old) receiving intraperitoneal bevacizumab recruited into the REZOLVE study from six hospitals in New South Wales, Queensland and Victoria, Australia. Baseline data includes demographics, ECOG performance status, prior systemic treatment, doses of the intervention administered, clinical chemistry, quality of life, adverse events and overall survival. Follow-up data was collected within three months after the first intraperitoneal administration of bevacizumab and includes adverse events and quality of life. The file type is .XLS.&rft.creator=Sjoquist, Katrin &rft.creator=Australia New Zealand Gynaecological Oncology Group &rft.creator=SHP-CTC node &rft.date=2024&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000801910&rft_rights=DATA SHARING GUIDELINES https://ctc.usyd.edu.au/our-research/research-areas/evidence-integration/current-key-projects/hesanda/&rft_subject=Oncology&rft.type=dataset&rft.language=English Access data via landing page
Cite Saved to MyRDA Save to MyRDA

Full description

This dataset includes 24 female participants (38 86 years old) receiving intraperitoneal bevacizumab recruited into the REZOLVE study from six hospitals in New South Wales, Queensland and Victoria, Australia. Baseline data includes demographics, ECOG performance status, prior systemic treatment, doses of the intervention administered, clinical chemistry, quality of life, adverse events and overall survival. Follow-up data was collected within three months after the first intraperitoneal administration of bevacizumab and includes adverse events and quality of life. The file type is .XLS.

Notes

HeSANDA 1.0.0

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related People

Subjects
Oncology |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers